Andere Sprachen DermTech, Inc.

Aktien

A2P4EG

US24984K1051

DMTK

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 24.04.2024			% 5 Tage	% 1. Jan.
0.614 ^USD	-0.32%		+3.72%	-64.91%

19.04.	DERMTECH, INC. : Lake Street gibt eine neutrale Bewertung ab	ZM
19.04.	DERMTECH, INC. : BTIG revidiert seine Meinung und wendet sich an Neutral	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

North American Morning Briefing : Stock Futures -2-	22.04.
DermTech Explores Strategic Alternatives to Boost Shareholder Value, Lays Off 100 Employees in Restructuring Plan	18.04.
DermTech to Explore Strategic Alternatives and Implement Restructuring Plan	18.04.
DermTech to Explore Strategic Alternatives and Implement Restructuring Plan	18.04.
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01.04.
DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology	11.03.
DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology	08.03.
DermTech : 2023 Q4 Transcript	01.03.
DermTech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.02.
DermTech, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29.02.
Earnings Flash (DMTK) DERMTECH Reports Q4 Revenue $3.9M, vs. Street Est of $4.03M	29.02.
DermTech Reports Fourth-Quarter 2023 Financial Results	29.02.
DermTech Announces Release Date for Fourth-quarter 2023 Financial Results	13.02.
DermTech Announces Additional Restructuring Actions to Focus on Revenue Growth and Streamline Operations	31.01.
Dermtech, Inc. Announces Cessation of Claudia Ibarra as Chief Operating Officer	31.01.
DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test across All Skin Types	19.01.
DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test (DMT) Across All Skin Types	18.01.
DermTech Announces Positive Topline Results from A Study Evaluating the Dermtech Melanoma Test Across All Skin Types	18.01.
DERMTECH SIMPLIFIES THE DERMTECH MELANOMA TEST BY DISCONTINUING THE OPTIONAL TERT ADD-ON ASSAY	17.01.
DermTech Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-on Assay	16.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen DermTech, Inc.

Aktien

A2P4EG

US24984K1051

DMTK

Andere Sprachen

Filter